Compare IBRX & CHWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | CHWY |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.8B |
| IPO Year | 2015 | 2019 |
| Metric | IBRX | CHWY |
|---|---|---|
| Price | $6.09 | $19.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 27 |
| Target Price | $14.25 | ★ $28.35 |
| AVG Volume (30 Days) | ★ 12.0M | 6.0M |
| Earning Date | 11-09-2026 | 12-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ 0.42 |
| Revenue | $113,288,000.00 | ★ $12,601,500,000.00 |
| Revenue This Year | $99.98 | $7.32 |
| Revenue Next Year | $108.29 | $6.74 |
| P/E Ratio | ★ N/A | $48.46 |
| Revenue Growth | ★ 668.31 | 6.24 |
| 52 Week Low | $1.95 | $17.40 |
| 52 Week High | $12.43 | $37.34 |
| Indicator | IBRX | CHWY |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 37.23 |
| Support Level | N/A | $17.49 |
| Resistance Level | $8.62 | $22.31 |
| Average True Range (ATR) | 0.57 | 0.85 |
| MACD | -0.10 | -0.38 |
| Stochastic Oscillator | 10.19 | 0.47 |
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Founded in 2011, Chewy is a leading e-commerce retailer of pet food, toys, supplies, and medications in North America. The firm offers a comprehensive selection of proprietary and third-party brands, anchored by its highly sticky autoship subscription program, which drives over 83% of its sales. Beyond core retail, Chewy is expanding into high-margin revenue streams, including its retail media network (Chewy Ads), specialized veterinary healthcare software, and brick-and-mortar veterinary clinics to further integrate customers into the Chewy ecosystem.